Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Shares Purchased by Northern Trust Corp

Northern Trust Corp lifted its stake in Tevogen Bio Holdings Inc. (NASDAQ:TVGN) by 13.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 118,415 shares of the company’s stock after acquiring an additional 13,595 shares during the quarter. Northern Trust Corp owned 0.07% of Tevogen Bio worth $122,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in TVGN. China Universal Asset Management Co. Ltd. acquired a new stake in Tevogen Bio during the 4th quarter worth approximately $38,000. JPMorgan Chase & Co. lifted its holdings in Tevogen Bio by 74.2% during the 4th quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company’s stock worth $40,000 after buying an additional 16,695 shares in the last quarter. Barclays PLC lifted its holdings in Tevogen Bio by 39.2% during the 4th quarter. Barclays PLC now owns 45,600 shares of the company’s stock worth $48,000 after buying an additional 12,847 shares in the last quarter. XTX Topco Ltd acquired a new stake in Tevogen Bio during the 4th quarter worth approximately $55,000. Finally, Geode Capital Management LLC lifted its holdings in Tevogen Bio by 31.2% during the 4th quarter. Geode Capital Management LLC now owns 451,851 shares of the company’s stock worth $465,000 after buying an additional 107,566 shares in the last quarter.

Analyst Ratings Changes

Separately, D. Boral Capital reiterated a “buy” rating and set a $10.00 target price on shares of Tevogen Bio in a report on Tuesday, May 27th.

Tevogen Bio Price Performance

NASDAQ TVGN opened at $1.28 on Wednesday. Tevogen Bio Holdings Inc. has a 52-week low of $0.26 and a 52-week high of $3.09. The business’s 50-day moving average price is $1.10 and its 200 day moving average price is $1.21.

Insiders Place Their Bets

In other Tevogen Bio news, insider Neal Flomenberg sold 232,968 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $1.09, for a total value of $253,935.12. Following the transaction, the insider now directly owns 3,595,608 shares of the company’s stock, valued at approximately $3,919,212.72. The trade was a 6.08% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last ninety days, insiders sold 391,871 shares of company stock valued at $428,025. 73.24% of the stock is owned by company insiders.

Tevogen Bio Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.